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Simple Summary: E-cigarettes are popular for smoking cessation but knowledge of their effect on
cardiovascular health is limited. We compared the short-term cardiovascular effects in 248 smokers
who quit smoking using e-cigarettes with or without nicotine or prescription nicotine replacement
therapy (NRT). All participants received behavioural support. We assessed the cardiovascular effects
of these stop smoking methods 3 days following quit date. Our work suggests that e-cigarettes offer
similar vascular health benefits to that of NRT. This happens at a very early stage in the stop smoking
process (3 days).
Abstract: Smoking increases cardiovascular disease (CVD) risk by leading to endothelial injury.
E-cigarettes remain a popular way to stop smoking. Evidence on their effect on cardiovascular health
is growing but remains limited, particularly in the short-term. The main objective of this study was
to compare short-term cardiovascular effects in smokers who quit smoking using e-cigarettes with
or without nicotine or prescription nicotine replacement therapy (NRT). This was a single-centre
(Sheffield, UK) pragmatic three-arm randomised controlled trial which recruited adult smokers
(≥10 cigarettes per day), who were willing to attempt to stop smoking with support (n = 248). Partic-
ipants were randomised to receive either: (a) behavioral support and e-cigarettes with 18 mg/mL
nicotine (n = 84); (b) behavioral support and e-cigarettes without nicotine (n = 82); (c) behavioral
support and NRT (n = 82). Flow Mediated Dilation (%FMD), peak cutaneous vascular conductance
responses to acetylcholine (ACh) and sodium nitroprusside (SNP) and mean arterial pressure (MAP)
were recorded at baseline and three days after stopping smoking. General Linear Models were used to
compare changes between groups and changes from follow-up. Adjusting for baseline, at follow-up,
all outcomes (for the 208 participants that completed the 3-day assessments) with the exception
of SNP had improved significantly over baseline and there were no differences between groups
(%FMD F = 1.03, p = 0.360, df = 2,207; ACh F = 0.172, p = 0.84, df = 2,207; SNP F = 0.382, p = 0.68,
df = 2,207; MAP F = 0.176, p = 0.84, df = 2,207). For smokers≥20 cigarettes per day, benefits were also
pronounced. Smoking cessation showed positive cardiovascular impact even after a 3-day period
and the effects did not differ between nicotine-containing e-cigarettes, nicotine-free e-cigarettes and
NRT.
Keywords: CVD; smoking cessation; vaping; nicotine replacement therapy; vascular function
1. Introduction
Smoking increases CVD risk by leading to endothelial injury and dysfunction in both
coronary and peripheral arteries [1]. It also produces an atherogenic lipid profile, primarily
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due by increasing triglycerides and decreasing high-density lipoprotein cholesterol [1].
Active smoking is only part of the problem, as it is now accepted that passive smoking
increases heart disease death-risk by almost 30% [2].
Smoking cessation reduces the excess risk, offering cardiovascular disease risk benefits,
both in the short- and in the long-term [3]. However, stopping smoking is a difficult process
and pharmacological interventions, particularly using two forms of nicotine replacement
therapy (NRT) or varenicline, rarely succeed on their own. This is why the combination of
behavioural support and these pharmacological interventions is considered as the most
effective approach [4–6], albeit with high relapse rates [7].
Vaping products or electronic cigarettes (e-cigarettes) have become popular as smok-
ing cessation aids. In England, these have been the most popular choice of support for
smoking cessation since 2013 and by 2018/19 were being used by about 30% of smokers
making a cessation attempt [8]. Evidence from different sources indicates that they are
effective for smoking cessation at least in the British context [9–11]. In a recent randomised
controlled trial [12], e-cigarettes with behavioural support were about twice as efficacious
as combination NRT with behavioural support in achieving long-term cessation (18.0%
versus 9.9%, relative risk = 1.83, 95% CI: 1.30–2.58).
There is a lack of evidence on the effect of e-cigarettes on cardiovascular health. Al-
though systematic reviews of e-cigarettes and cardiovascular effects suggest that there is
potential for cardiovascular harm [13], the risk is expected to be less than that of cigarette
smoking [14]. Furthermore, a recent, randomised controlled trial, which assessed cardiovas-
cular effects of switching from smoking to e-cigarettes after one month, found significant
improvements in endothelial function and vascular stiffness, two indicators for increased
CVD risk [12]. Although this information is useful, additional information on the timing
of improvements (particularly as of when any improvements are initiated), as well as a
comparison to NRT and the use of additional cardiovascular outcome measures (e.g., to
assess microvascular function) would be valuable to obtain a more comprehensive picture
and help us understand how e-cigarettes physiologically affect smokers, who wish to stop
smoking by using them.
Therefore, the aim of the present study was to compare short-term (3-day) cardiovascu-
lar effects in smokers who had quit smoking, using behavioural support and (a) e-cigarettes
with nicotine, (b) e-cigarettes without nicotine, (c) prescription NRT. Medium- and longer-
term effects will be reported separately.
2. Methods
The full protocol has been published elsewhere [15].
2.1. Design and Setting
This single-centre pragmatic three-arm randomised controlled trial was conducted in
Sheffield, UK; participants were recruited between May 2017 and June 2019.
2.2. Participant Recruitment
Participants were recruited from the community in the wider Sheffield area [15].
Eligible were smokers who had smoked ≥10 cigarettes per day for the last year, were aged
≥18 and willing to attempt to stop smoking, using a stop smoking service or e-cigarettes.
Exclusion criteria were inability to walk, recent (i.e., within 6 months) CVD events or cardiac
surgery, insulin-controlled diabetes mellitus or coexisting skin conditions, leg ulceration,
vasculitis or deep venous occlusion, pregnancy, major surgery scheduled during the study,
contra-indications or unsuitability for NRT, current daily use of e-cigarettes and current
cessation attempt supported by a stop smoking service.
2.3. Procedures
Following a telephone pre-screening and information about study procedures, par-
ticipants were invited to the Centre for Sport and Exercise Science of Sheffield Hallam
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University to provide informed consent and undertake baseline assessments. Participants
were enrolled by a researcher not involved in group allocation, intervention delivery or
assessments. Following this visit, participants were randomised remotely into three groups
by an independent statistician using a computer-generated (nQuery Advisor 6.0, Statistical
Solutions, Ireland) block-randomisation stratified by gender and “pack-years” (number
of packs (20 cigarettes per pack) per day times number of years smoked). The study
statistician allocated a unique trial number to each participant for the study duration.
Outcome assessors were blinded to group allocation and participants were reminded
regularly not to share their group allocation with assessors or those providing behavioural
support. The study statistician and health economist were blinded to group allocation.
Those delivering the intervention were only blinded in relation to which e-cigarette group
the participants belonged to as the NRT group was receiving support through the stop
smoking service. Participants were not blinded, as NRT was delivered separately, and the
e-cigarette groups were able to determine the presence or absence of nicotine.
During their initial behavioural support sessions, participants set a “quit date”, on
which they would stop smoking completely. This defined timing of follow-up visits.
2.4. Intervention
Group A and B: Both groups received behavioural support for a 3-month period.
Following allocation, Groups A and B received complimentary e-cigarette equipment and
refills (Tornado V5, Totally Wicked, Blackburn, UK), together with instructions on the
correct usage of e-cigarettes. In both groups, participants on average received 20 bottles of
10 mL during the three-month period. Group A received nicotine-containing liquids with
nicotine strength of up to 18 mg/mL. Participants could choose ice menthol or tobacco
flavour (Red Label, Totally Wicked). Group B received nicotine-free liquids (0 mg/mL)
with the same choice of flavours as Group A.
Group C: Following allocation, Group C participants were referred to Sheffield stop
smoking services, where they received behavioural support for three months. Group C re-
ceived money or shopping vouchers (depending on personal preference) as reimbursement
for NRT prescription charges for the intervention period.
To ensure comparability of behavioural support provided, all groups received the
same level and type of behavioural support as currently offered as standard by stop
smoking services, in the form of regular face-to-face or telephone appointments as per
relevant guidelines, e.g., minimum of 6 support sessions within the 3-month period [16].
All advisors had completed the same behavioural support training.
2.5. Measures
2.5.1. Baseline
Measures included age, gender, body mass index, blood pressure, number of cigarettes
and years smoked. Physical activity was measured using the SF-IPAQ [17]. Activities
lasting >10 min were included, with each activity > 3 h truncated to 180 min for analysis.
To arrive at a weekly figure, the metabolic equivalent (MET) value score (walking = 3.3,
moderate activity = 4, vigorous activity = 8) was multiplied by the minutes the activity
was carried out and again by the number of days that activity was undertaken. Additional
clinical history, quality of life and CVD risk were recorded but not included in the present
analysis.
The same assessor was responsible for all macro- and micro-vascular assessments.
Macrovascular function was assessed using percentage change in Flow Mediated Dilation
(%FMD). Smoking is associated with reduced FMD. Reduced altered brachial artery FMD is
an early marker for endothelial dysfunction, a CVD risk factor [1] and can predict long-term
adverse cardiovascular events [18]. FMD is a non-invasive, nitric oxide-mediated measure.
Baseline scanning to assess resting vessel diameter were recorded over 3 min, following a
10-min resting period, using a Nemio XG (Toshiba, Tokyo, Japan) ultrasound machine. A
12 MHz linear transducer was used to image the brachial artery as per the International
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Brachial Artery Reactivity Task Force guidelines [19]. A sphygmomanometric cuff placed
on the forearm was inflated at least 50 mmHg above systolic pressure to occlude artery
inflow for 5 min. Recordings commenced 30 s before cuff deflation and continued for 3 min
after [19]. The technical error in our lab for FMD is 5%. FMD is presented as change in
post-stimulus diameter as percentage of the baseline diameter (%FMD).
Upper-body microvascular function was assessed using peak cutaneous vascular
conductance (CVC) responses to acetylcholine (ACh) and sodium nitroprusside (SNP) as
indicators of microvascular endothelial-dependent and -independent vasodilation, respec-
tively, measured using Laser Doppler Fluximetry and Iontophoresis [20]. Measurements
were performed in a temperature-controlled room (22–24 ◦C) in the ventral surface of the
right arm extended to the side at heart level. Heart rate (Sports Tester, Polar, Finland) and
blood pressure (left arm; Dinamap Dash 2500, GE Healthcare, Chicago, Illinois, USA) were
monitored at 5-min intervals throughout the protocol.
Mean arterial pressure (MAP) was calculated using the following formula:
(2× Diastolic Pressure) + Systolic Pressure
3
To obtain an index of skin blood flow, cutaneous red cell flux was measured by placing
an iontophoresis laser Doppler probe (PF481-1; Perimed AB, Jarfalla, Sweden), connected
to a laser Doppler fluxmeter (PF5001; Perimed AB), in the centre of each drug delivery
electrode. The two drug delivery electrodes (PF383; Perimed AB) were positioned over
healthy looking skin, approximately 4 cm apart with one containing 100 µL of 1% ACh
(Miochol-E, Novartis, Stein, Switzerland—endothelium dependent vasodilator) and the
other 100 µL of 1% SNP (Nitroprussiat, Rottapharm, Barcelona, Spain)—endothelium
independent vasodilator). For additional details see Box 1. Measurements of red cell flux
(recorded in arbitrary units, AU) were divided by corresponding MAP values (in mmHg)
to give CVC in AU/mmHg. Here we present ACh and SNP peak CVC responses. The
technical error of measurement for drug-induced, peak flux responses in our laboratory is
15% [21].
Box 1. The iontophoresis protocol.
Timeline Duration
Baseline recording period 4 min
1st Dose (0.2 mA→ 2 mC) 10 s
2nd Recording period 4 min
2nd Dose (0.2 mA→ 3 mC) 15 s
3rd Recording period 4 min
3rd Dose (0.2 mA→ 4 mC) 20 s
4th Recording period 4 min
4th Dose (0.3 mA→ 6 mC) 20 s
5th Recording period 4 min
mA: micro-amber, mC: micro-coulomb.
2.5.2. Outcomes
Outcome measures (Box 2) were recorded three days after the quit date, when all in-
cluded participants reported abstinence from smoking, biochemically-validated by exhaled
air measurement of <10 ppm carbon monoxide [22], with them confirming that they were
following the allocated treatment. The primary outcome measure was %FMD. Secondary
outcome measures were CVC max responses to ACh and SNP, and MAP (assessed as at
baseline).
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Box 2. Reasons of Choice of Main Outcome Measures.






It is a non-invasive, highly
reproducible assessment. Reduced
altered brachial artery FMD is
considered an early marker for
endothelial dysfunction, a CVD risk











It is the only non-invasive measure
that can assess reliably
endothelial-dependent vasodilatory
function in general and NO









cell function at microvascular
level).
It is the only non-invasive measure
that can assess reliably
endothelial-independent
vasodilatory function. Smooth
muscle cells are the most numerous
components of the arterial and
venous wall, playing a key role in
vasodilation and in the progression





(surrogate marker for arterial
stiffness).
This is a readily available,
non-invasive measure (i.e.,
measured through Systolic and
Diastolic blood pressure
measurements), that can indicate
changes in arterial stiffness when
direct measures (e.g., pulse wave
velocity) are not available or there is
a need to reduce participant
burden.
2.5.3. Statistical Analysis
To compare changes between groups and changes from follow-up, data were analysed
using General Linear Model (Univariate Analysis of Variance) with linear contrast, unad-
justed and adjusted for their baseline measures with/without inclusion of covariates. For
ACh and SNP, the model included BMI, age, gender, group, and years smoked. For MAP
and %FMD, BMI was replaced with baseline weekly physical activity (SF-IPAQ MET).
As additional post-hoc analyses, models were run with BMI, age, gender, group, phys-
ical activity, and years smoked for a sub-sample including those smoking ≥20 cigarettes
daily (n = 89 at follow-up). Although the association between exposure and cardiovascular
effects is non-linear and evident even among smokers of few cigarettes, those smoking
more heavily are at higher risk of cardiovascular disease [1].
Data were analysed in SPSS 24 (IBM U.K. Limited, Hampshire, UK), using an intention-
to-treat approach. Missing values due to equipment malfunction were replaced by the
group mean values in their respective participant’s group [23]. Statistical tests’ significance
was set at p ≤ 0.05. Effect size partial η2 was calculated and considered “large” if >0.138,
“medium” if between 0.06–0.138, and “small” if <0.06 [24].
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3. Results
3.1. Participants
In total, 248 participants were randomised (Figure 1). Information about their baseline
characteristics is presented in Table 1. Of those, micro-vascular function was unavailable
for 7 participants (Group A (nicotine-containing e-cigarettes) = 3, Group B (nicotine-free
e-cigarettes) = 3, Group C (NRT) = 1). Of the randomised participants, 208 (84%) completed
the follow-up visit.
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Nicotine-Free  
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(NRT), n = 82 
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Age, Mean years (SD) 44 (14) 44 (13) 44 (13) 
BMI a, Mean (SD) 27.6 (5.9) 27.3 (5.4) 26.3 (5.1) 
Smoking Years, Mean (SD) 24 (13) 25 (13) 25 (13) 
Cigarettes per day, Mean (SD) 18 (7) 16 (7) 18 (7) 
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Figure 1. Flowchart of the Study Population.
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Table 1. Sample description, n = 248.
Baseline Characteristics Nicotine-ContainingE-Cigarettes, n = 84
Nicotine-Free




Sex, Female/Male, n 46/38 41/41 36/46
Age, Mean years (SD) 44 (14) 44 (13) 44 (13)
BMI a, Mean (SD) 27.6 (5.9) 27.3 (5.4) 26.3 (5.1)
Smoking Years, Mean (SD) 24 (13) 25 (13) 25 (13)
Cigarettes per day, Mean (SD) 18 (7) 16 (7) 18 (7)
Percentage of Heavy Smokers (≥20 cigarettes
per day), Mean (SD) 48% 36% 49%
Smoking packet years, Mean (SD) 23 (17) 22 (17) 24 (19)
Exhaled air carbon monoxide, Mean parts
per million (SD) 15.2 (7.9) 14.3 (8.1) 16.9 (6.9)
Physical Activity, Mean weekly MET b
minutes (SD)
2772 (2669) 3082 (3191) 2756 (2627)
Artery Diameter (pre-inflation), Mean (SD) 4.22 (0.66) 4.13 (0.65) 4.10 (0.56)
Artery Diameter (post-inflation), Mean (SD) 4.47 (0.64) 4.34 (0.61) 4.36 (0.55)
%FMD c, Mean (SD) 6.2 (4.4) 5.6 (3.6) 6.7 (4.0)
Baseline flow (mL/min) 115.8 (74.8) 116.1 (73.5) 116.3 (73.5)
Reactive hyperaemia blood flow (mL/min) 676.8 (269.3) 678.5 (270.7) 674.5 (263.1)
Peak CVC d for Ach e, Mean PU/mmHg (SD) 1.48 (1.02) 1.49 (0.98) 1.34 (1.00)
Peak CVC for SNP f, Mean PU/mmHg (SD) 1.45 (1.02) 1.15 (0.72) 1.35 (0.98)
MAP g, Mean mm Hg (SD) 98.3 (11.3) 97.4 (12.2) 98.2 (11.5)
a BMI: Body Mass Index; b MET: Metabolic Equivalent; c %FMD: Percentage change in Flow Mediated Dilation; d CVC: Peak cutaneous
vascular conductance; e ACh: Acetylcholine; f SNP: Sodium nitroprusside; g MAP: Mean Arterial Pressure.
3.2. Primary Outcome: Macrovascular Assessment
At follow-up, %FMD showed an improvement over baseline in all three groups
(F = 8.99, df = 3,207; p < 0.001, with baseline %FMD: p < 0.001), with a medium effect size
(η2 = 0.117). There was no statistically significant difference in %FMD between groups
(Table 2). In analysis adjusting for group, physical activity (p < 0.02), age, gender (p < 0.02)
and years smoked, the improvement in effect size from baseline to follow-up recorded
(F = 5.75, df = 7,207; p < 0.001, effect size η2 = 0.167 ‘large’), with no significant difference
between groups (Table 2; Figure 2A).
3.3. Secondary Outcomes: Microvascular Assessment
3.3.1. Acetylcholine (ACh)
CVC values for ACh improved significantly over baseline in all three groups (F = 8.43,
df = 3,207; p < 0.001, baseline ACh p < 0.001; with a medium effect size η2 = 0.110) and there
was no difference between groups at follow-up (Table 2). The improvement from baseline
was also evident with increased effect size in the models adjusting for BMI (p < 0.04), age,
group, gender and years smoked (F = 4.73, df = 7,207; p < 0.001, η2 = 0.145 ‘large’ effect
size) and there was no statistical difference between groups (Table 2; Figure 2B).
3.3.2. Sodium Nitroprusside (SNP)
Although CVC values for SNP appeared to improve over the baseline, the model of
adjusted mean over baseline values was not significant (F = 0.73, df = 3,207; p = 0.54, with
a small effect size η2 = 0.011) and this remained when adjusting for BMI, age, gender and
years smoked (F = 1.00, df = 3,207; p = 0.44, η2 = 0.034). There was no statistically-significant
difference between groups (Table 2; Figure 2C).
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Table 2. Presentation of the results for the General Linear Model for all outcomes at 3 days post quit in all participants.
3 Days Post Quit Nicotine-ContainingE-Cigarettes, n = 69
Nicotine-Free
E-Cigarettes, n = 67
Nicotine Replacement
Therapy (NRT), n = 73
F Value, p Value and
Degrees of Freedom η
2
%FMD a,b
Unadjusted, Mean (SD) 9.0 (4.1) 10.2 (5.2) 9.4 (4.5) F = 1.03, p = 0.360, df = 2,207 0.01
Adjusted for baseline, Mean (95% C.I.) 9.0 (7.9–10.0) 10.3 (9.2–11.4) 9.4 (8.4–10.5) F = 8.99, p < 0.001, df = 3,207 0.117
Fully adjusted, Mean (95% C.I.) 9.0 (7.9–10) 10.3 (9.2–11.3) 9.5 (8.4–10.5) F = 5.75, p < 0.001, df = 7,207 0.167
Peak CVC c for ACh d,e
Unadjusted Mean PU/mmHg (SD) 1.64 (1.06) 1.76 (1.42) 1.64 (1.18) F = 0.172, p = 0.84, df = 2,207 0.001
Adjusted for baseline, Mean PU/mmHg (95% C.I.) 1.64 (1.38–1.91) 1.73 (1.46–2.01) 1.68 (1.42–1.95) F = 8.43, p < 0.001, df = 3,207 0.110
Fully adjusted, Mean PU/mmHg (95% C.I.) 1.63 (1.37–1.90) 1.77 (1.49–2.05) 1.67 (1.38–1.91) F = 4.73, p < 0.001, df = 7,207 0.145
Peak CVC for SNP e,f
Unadjusted Mean PU/mmHg (SD) 1.65 (1.17) 1.71 (1.61) 1.50 (1.21) F = 0.382, p = 0.68, df = 2,207 0.004
Adjusted for baseline, Mean PU/mmHg (95% C.I.) 1.62 (1.31–1.93) 1.71 (1.39–2.03) 1.49 (1.19–1.80) F = 0.73, p = 0.54, df = 3,207 0.011
Fully adjusted, Mean PU/mmHg (95% C.I.) 1.61 (1.30–1.92) 1.72 (1.40–2.05) 1.52 (1.21–1.83) F = 1.00, p = 0.44, df = 7,207 0.034
MAP g
Unadjusted, Mean mmHg (SD) 95.7 (11.1) 96.6 (12.3) 95.9 (11.4) F = 0.176, p = 0.84, df = 2,207 0.002
Adjusted for baseline, Mean mmHg (95% C.I.) 94.3 (93.3–97.4) 96.3 (95.4–98.6) 95.4 (95.1–98.3) F = 72.42, p < 0.001, df = 3,207 0.516
Fully adjusted, Mean mmHg (95% C.I.) 94.3 (93.3–97.4) 96.3 (95.4–98.6) 95.4 (95.1–98.3) F = 34.23, p < 0.001, df = 7,207 0.545
a %FMD: Percentage change in Flow Mediated Dilation; b Fully adjusted models for FMD and MAP include age, gender, years smoked, physical activity (weekly MET minutes) in addition to baseline measure of
outcome.; c CVC: Peak cutaneous vascular conductance; d ACh: Acetylcholine; e Fully adjusted models for ACh and SNP include BMI, age, gender, years smoked in addition to baseline measure of outcome.;
f SNP: Sodium nitroprusside; g MAP: Mean Arterial Pressure.
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Figure 2. Changes from baseline to follow-up by treatment arm in (A): Flow mediated dilation (%FMD); (B): Peak cutaneous
vascular conductance responses to acetylcholine (ACh); (C): Peak cutaneous vascular conductance responses to sodium
nitroprusside (SNP); (D): Mean arterial pressure (MAP).
3.3.3. Mean Arterial Pressure (MAP)
MAP readings were reduced in all groups (F = 72.42, df = 3,207; p < 0.001; baseline
MAP p < 0.001), with a large effect size (η2 = 0.516) and no difference b tween groups
(Table 2). The reductions remai ed w en including physical activity (p = 0.02), age, group,
gender (p = 0.02) and years smoked as co-variates (F = 34.23, df = 7,207; p < 0.001, η2 = 0.545)
with no statistically-significant difference between groups (Table 2; Figure 2D).
3.4. Heavy Smokers Subgroup
The post-hoc analysis for both primary (%FMD) and secondary outcome measures
(ACh, SNP, MAP) showed stronger effects than in the full sample, particularly for %FMD
(F = 14.53, df = 7,88; p < 0.001; η2 = 0.268; Table 3), for which group (p = 0.04) and physical
activity (p < 0.001) were statistically significant covariates, in the fully-adjusted model.
FMD improved more in the nicotine-free e-cigarette group than the nicotine-containing
e-cigarette group (mean difference = 3.167 (0.590–5.744); p = 0.01). Statistical significance
was reached for MAP (F = 4.24, p < 0.001, df = 7,88; η2 = 0.557), with gender (p = 0.02) and
physical activity (p = 0.04) being statistically-significant covariates.
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Table 3. Presentation of the results for the General Linear Model for all outcomes at 3 days post quit in subgroup analysis of smokers smoking ≥20 cigarettes per day (Heavy Smokers).
3 Days Post Quit Nicotine-ContainingE-Cigarettes, n = 35
Nicotine-Free
E-Cigarettes, n = 30
Nicotine Replacement
Therapy (NRT), n = 24
F Value, p Value and
Degrees of Freedom η
2
%FMD a,b
Unadjusted, Mean (SD) 8.4 (3.9) 10.7 (6.0) 10.0 (4.8) F = 1.672, p = 0.19, df = 2,88 0.038
Adjusted for baseline, Mean (95% C.I.) 8.1 (6.4–9.8) 11.0 (9.1–13.0) 10.2 (8.6–11.8) F = 5.53, p < 0.01, df = 3,88 0.163
Fully adjusted, Mean (95% C.I.) 8.1 (6.4–9.8) 11.2 (9.4–13.1) 10.1 (8.6–11.7) F = 14.53, p < 0.001, df = 7,88 0.268
Peak CVC c for ACh d,e
Unadjusted Mean PU/mmHg (SD) 1.73 (1.17) 1.31 (0.77) 1.80 (1.25) F = 1.371, p = 0.26, df = 2,88 0.031
Adjusted for baseline, Mean PU/mmHg (95% C.I.) 1.75 (1.37–2.12) 1.36 (0.94–1.78) 1.76 (1.41–2.11) F = 3.98, p < 0.01, df = 3,88 0.123
Fully adjusted, Mean PU/mmHg (95% C.I.) 1.70 (1.34–2.06) 1.38 (0.94–1.82) 1.70 (1.34–2.06) F = 2.24, p < 0.04, df = 7,88 0.168
Peak CVC for SNP f,e
Unadjusted Mean PU/mmHg (SD) 1.41 (0.84) 1.42 (1.34) 1.56 (1.27) F = 0.17, p = 0.84, df = 2,88 0.004
Adjusted for baseline, Mean PU/mmHg (95% C.I.) 1.39 (0.99–1.79) 1.48 (1.02–1.93) 1.53 (1.15–1.90) F = 1.14, p = 0.38, df = 3,88 0.039
Fully adjusted, Mean PU/mmHg (95% C.I.) 1.36 (0.95–1.78) 1.50 (1.02–1.98) 1.56 (1.20–1.98) F = 1.04, p = 0.41, df = 7,88 0.085
MAP g,b
Unadjusted, Mean mmHg (SD) 99 (13) 99 (12) 97 (11) F = 0.77, p = 0.47, df = 2,88 0.018
Adjusted for baseline, Mean mmHg (95% C.I.) 98 (95–101) 99 (96–102) 98 (95–101) F = 29.25, p < 0.001, df = 3,88 0.508
Fully adjusted, Mean mmHg (95% C.I.) 97 (94–100) 99 (97–102) 98 (95–101) F = 4.24, p < 0.001, df = 7,88 0.557
a %FMD: Percentage change in Flow Mediated Dilation; b Fully adjusted models for FMD and MAP include age, gender, years smoked, physical activity (weekly MET minutes) in addition to baseline measure of
outcome.; c CVC: Peak cutaneous vascular conductance; d ACh: Acetylcholine; e Fully adjusted models for ACh and SNP include BMI, age, gender, years smoked in addition to baseline measure of outcome.;
f SNP: Sodium nitroprusside; g MAP: Mean Arterial Pressure.
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4. Discussion
In this trial, smokers who had quit three days ago showed clear improvements in dif-
ferent indicators of cardiovascular risk (except for SNP-assessed, endothelial-independent
vasodilation). This improvement was the same for smokers using NRT, an e-cigarette with
nicotine or an e-cigarette without nicotine. “Heavy smokers” (i.e., those smoking more
than 20 cigarettes/day) appeared to benefit as well.
E-cigarettes are thought to increase oxidative stress levels and consequently have
a negative acute effect on NO-bioavailability and endothelial function of healthy adults
(who in theory have an “intact” endothelium) [24], although this view has recently been
challenged [25]. Nevertheless, as our results indicate at both micro- and macro-vascular
levels, these negative effects are less pronounced for smokers (whose endothelium is
already and largely affected by smoking), who make a smoking cessation attempt using
e-cigarettes or NRT. ACh is a microvascular, endothelial-dependent vasodilator, primarily
associated with an increase in NO bioavailability, especially when higher doses are given,
as in our study [23]. Similarly, endothelium-derived NO is considered to be a principal
mediator for FMD [23], although this is questioned by some researchers [26]. As both were
improved, 3-days after smoking cessation, an endothelial function improvement can be
safely assumed. These findings are partially supported by the work of Carnevale et al. [24],
who found the effects of e-cigarettes to be less pronounced than those caused by traditional
tobacco cigarettes, especially regarding the levels of oxidative stress and NO bioavailability
and to that of Haptenstall et al. [25], who found that acute e-cigarette use does not affect
FMD values in smokers.
We can also accept that the observed MAP reduction suggests to some extent a reduc-
tion in arterial stiffness [27]. This is because as MAP rises, the arterial segment experiences
increased circumferential pressure with greater recruitment of inelastic collagen fibres,
which in turn leads to higher measured stiffness [28]. Arterial stiffness is associated with
vascular damage, independently-related to adverse cardiovascular outcomes across many
different patient groups and in the general population [24]. An alternative explanation for
the MAP reduction in the non-nicotine study arms (i.e., NRT and nicotine-free e-cigarettes),
could be the reduced sympathetic activation due to lower overall intake of sympath-
omimetic agents such as nicotine and particulate matter in the arms [29]. However, the fact
that this reduction was a common finding among all groups suggests that the prevailing
mechanism is different.
Therefore, stopping smoking through either NRT or e-cigarettes offers immediate
benefits at both micro- and macro-circulatory levels. Recent work [12] reported that
endothelial function and arterial stiffness in e-cigarette groups improved within 1 month
of switching. The present study shows that endothelial function improves much earlier.
This is an important physiological observation for the general smokers’ population, who
wish to stop smoking, as the early reversal of the smoking-induced, vascular dysfunction
can potentially infer a lower CVD risk [30]. However, the effects of long-term smoking
abstinence while using e-cigarettes on both micro- and macro-circulatory levels remain to
be investigated, although these early signs are very positive.
At this instance, we found no improvement in SNP values: SNP is an endothelial-
independent vasodilator, acting through the smooth muscle cells of the micro vessels [20].
Smooth muscle cells are the most numerous components of the arterial and venous wall,
playing a key role in vasodilation and in the progression of pathological conditions such as
atherosclerosis [31]. Therefore, the lack of a statistically-significant improvement suggest
that positive vascular effects primarily occurred in the endothelium and not in the smooth
muscle (which is also affected by smoking). A longer-term observation would explore if,
and at which time-point, these can be reversed.
The present work suggests that overall, in the general smokers’ population, none of
the included smoking cessation methods appears to be superior over the other, in terms of
short-term cardiovascular benefits, which is in line with the existing literature [12]. Phar-
macological and toxicological studies support the biological plausibility that nicotine is an
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independent contributor to acute cardiovascular events and accelerated atherogenesis [11].
This is translated in lower FMD values (and potentially ACh-dependent microcirculatory
vasodilation), experienced even after acute nicotine exposure [30]. However, nicotine is not
the only constituent in smoking that impacts on cardiovascular function, e.g., CO reduces
the ability to transport oxygen, acrolein increases blood cholesterol etc. Therefore, there
are several elements that lead to vasoconstriction [11]. Consequently, despite the higher
FMD values in the non-nicotine groups, lack of a statistically-significant difference between
groups in the general smokers’ population, may suggest that the nicotine effect is one of
the last to be reversed—we would need further studies, which would explore when (and
if) the negative nicotine effect can be overturned.
Finally, a lower BMI and physical activity were associated with more beneficial
changes which are in line with previous evidence [32,33]. This can suggest that more
complex, lifestyle interventions are needed to reduce CVD risk to a greater extend.
4.1. Limitations
Since e-cigarettes had not been adopted as smoking cessation support option by the
involved stop smoking services, there were differences in the delivery of the intervention
between groups. However, as the main aim of this study is not to assess efficacy of the
different options but to compare their impact on cardiovascular function, this does not
affect our conclusions. Furthermore, nearly 16% of participants dropped out before the
3-day assessments—we are confident that their small number has not affected our findings.
There are many different device manufacturers as well as e-cigarette liquid producers
and a wide range of liquids available so the present findings may not be generalisable
to all types of devices and liquids. However, to ensure consistency and standardisation,
we used a single device and liquid manufacturer throughout our study. Data on actual
amount of e-liquid or NRT products used were not collected which could have provided
more fine-grained information on cardiovascular effects.
Additionally, a fault in the equipment led to loss of microcirculatory assessments both
at baseline and the 3-day visits for 7 participants, representing less than 3% of participants
split across all three groups. Finally, we did not include a group of continuing cigarette
smokers. However, all participants were smokers initially and therefore de-facto acted as
controls for themselves.
4.2. Strengths
This is the first study to compare the short-term cardiovascular effects of smoking
cessation using e-cigarettes and behavioral support with stop smoking service-delivered,
NRT supported smoking cessation. Processes followed during our intervention simulated
those that would be followed if e-cigarettes were widely adopted as a smoking cessation
aid, in supported smoking cessation attempts in the UK and beyond. The study included
an NRT-based smoking cessation group, as this represents a current common route for
those wishing to stop smoking through stop smoking services or by using NRT purchased
without a prescription. We explored both micro- and macro-circulation, as cardiovascular
disease presents itself in both—with recent work suggesting that pathological changes
in the microcirculation mirror [33] if not precede [34] changes in arteries, making it an
appropriate area to study to achieve early detection.
4.3. Future Research
Longer-term (≥6 months) studies will shed further light as to whether CVD-risk
reduction benefits persist, are increased or diminished. Moreover, additional mechanis-
tic, large-scale studies based on blood biomarkers would allow researchers to explore
mechanisms behind findings. This was not possible in the current study, due to funding
limitations.
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5. Conclusions
Smoking cessation showed positive cardiovascular impact on smokers making a stop
smoking attempt, even after a short, 3-day period. The positive effects did not differ
between nicotine-containing e-cigarettes, nicotine-free e-cigarettes and NRT. This suggests
that in the short-term, e-cigarettes offer similar vascular health benefits to that offered by
NRT, to smokers wishing to quit traditional cigarettes; thus, both e-cigarettes and NRT
can be considered as CVD risk-reduction measures. This should be further explored in
longer-term studies, so that stop smoking policies are scientifically informed.
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